FDAnews
www.fdanews.com/articles/197373-ciscrp-survey-reveals-optimism-about-timing-of-covid-19-vaccine-treatments

CISCRP Survey Reveals Optimism About Timing of COVID-19 Vaccine, Treatments

June 1, 2020

Sixty percent of the public surveyed say they believe a treatment or vaccine for COVID-19 will be developed in just under a year. And once developed, 64 percent said they thought it would be less than a year before the public could begin receiving a COVID-19 treatment or vaccine.

More North American respondents (21 percent) said it would take less than six months to develop a treatment or vaccine compared with European respondents (11 percent), according to a survey of 500 people conducted by the Center for Information and Study on Clinical Research Participation (CISCRP).

Up to 55 percent said they were willing to participant in a COVID-19 trial. More Europeans (60 percent) said they are “somewhat” or “very willing” to participate in a COVID-19 trial compared with those from North America (48 percent). Approximately 46 percent of respondents who indicated they were “somewhat” or “very willing” to participate in a COVID-19 study said they wanted to participate to advance science, help others with COVID-19 and to help researchers find a treatment for the virus. Only 17 percent and 29 percent of respondents said they wanted to participate to receive free medication or to receive money, respectively.

Of the 228 respondents who indicated they were “not sure,” “not at all” or “not very” willing to participate in a COVID-19 trial, 45 percent said they would not participate because they do not want to take a chance on their health.

In terms of trust, 49 percent of respondents said they held “some” trust in research centers and clinics, compared with only 29 percent of respondents who said they held “a lot” of trust in these centers. Around 50 percent said they held “some” trust in regulatory authorities, such as the FDA, and 47 percent of respondents said they held “some” trust in pharmaceutical companies. Only 17 percent of respondents reported having “a lot” of trust in pharmaceutical companies.

To see the full results of the survey, click here: www.fdanews.com/05-29-20-COVID19.pdf.